> About TAP
How similar is your antibody to clinical-stage therapeutics?
- To use this application, you only require an amino acid antibody variable domain heavy and light chain sequence.
- The Therapeutic Antibody Profiler (TAP) compares your antibody variable domain sequence against five developability guidelines derived from clinical-stage therapeutic values.
- TAP uses ABodyBuilder2 to generate a model structure of your antibody.
- TAP then calculates the following properties (explained in the paper) to see if your antibody design is commenserate with those of clinical-stage therapeutics:
- Total CDR Length
- Patches of Surface Hydrophobicity (PSH) metric across the CDR Vicinity
- Patches of Positive Charge (PPC) metric across the CDR Vicinity
- Patches of Negative Charge (PNC) metric across the CDR Vicinity
- Structural Fv Charge Symmetry Parameter (SFvCSP)
- TAP also outputs...
- An interactive representation of your antibody model, allowing you to visualise hydrophobic/charge patches on the Van der Waals surface. The model is downloadable.
- A representation showing predicted model accuracy from ABodyBuilder2
- Sequence liabilities likely to lead to post- or co-translational modification
- For a sample TAP output, please click here. More information about the guidelines and more resources can be found here.
For a full description of the TAP metrics, please refer to: Raybould MIJ, et al. Five Computational Developability Guidelines for Therapeutic Antibody Profiling. PNAS. (2019)
NB: The latest TAP protocol "TAP2" is summarised in Raybould MIJ, et al. Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling. Communications Biology. (2024)
> Resources
Please cite our paper "Five Computational Developability Guidelines for Therapeutic Antibody Profiling" if making use of these datasets.
- The 242 Clinical-Stage Therapeutics (CST) models that set the TAP Guidelines in the PNAS paper can be found here.
- The 242 CST sequences can be found in the paper SI here (Dataset S2).
- The TAP Guidelines were last updated on 24th February 2025. We are now tracking 851 post Phase-I therapeutic Fvs.
| Property | Amber Region (24th February 2025) | Red Region (24th February 2025) |
|---|---|---|
| Total CDR Length (L) | 37 ≤ L ≤ 42 | L < 37 |
| 55 ≤ L ≤ 65 | L > 65 | |
| Patches of Surface Hydrophobicity (PSH) | 95.77 ≤ PSH ≤ 111.40 | PSH < 95.77 |
| 167.64 ≤ PSH ≤ 211.65 | PSH > 211.65 | |
| Patches of Positive Charge (PPC) | 1.34 ≤ PPC ≤ 4.20 | PPC > 4.24 |
| Patches of Negative Charge (PNC) | 1.99 ≤ PNC ≤ 4.43 | PNC > 5.67 |
| Structural Fv Charge Symmetry Parameter (SFvCSP) | -30.60 ≤ SFvCSP ≤ -6.00 | SFvCSP < -30.60 |
Please visit Thera-SAbDab to access our latest CST sequence data.
